Skip to content

K-Stock Briefing

https://kstockbriefing.com

  • About Us
  • Weekly News
  • IR Room
  • RESEARCH
    • Semiconductors
  • Disclosures
    • Semiconductors
    • Energy
    • Bio & Healthcare
    • Defense
    • Shipbuilding
    • Automotive
  • Toggle search form
  • [Disclosure] ALTEOGEN (196170) – Closure of Shareholder Register or Setting of Record Date / 2024-12-12 Disclosures
  • [Disclosure] Hanwha Systems (272210) – Investor Relations (IR) Holding / 2025-10-31 Disclosures
  • [Disclosure] Hanwha Aerospace (012450) – Supply Contract / 2025-04-07 Disclosures
  • [Disclosure] Hanwha Ocean (042660) – Decision on Guarantees for Debt of Others / 2024-11-21 Disclosures
  • [Disclosure] HPSP (403870) – Execution of Stock Pledge Agreement Involving Change of Largest Shareholder / 2025-05-16 Semiconductors
  • [Disclosure] SK hynix (000660 / SKHY) – Decision on Acquisition of Shares and Investment Securities of Other Corporation (Correction Disclosure) / 2026-03-03 Semiconductors
  • [Disclosure] Celltrion (068270) – Approval of European Commission Marketing Authorization for Eydenzelt (CT-P42, Eylea Biosimilar) / 2025-02-14 Disclosures
  • [Research] SK hynix (000660 / SKHY) – Daishin | ADR Listing · HBM4 · Valuation Re-rating / 2026-07-07 RESEARCH

[Disclosure] Hanwha Systems (272210) – Decision on Capital Increase / 2025-06-25

Posted on June 25, 2025August 11, 2026 By K-STOCK Editor

Fact Source: Financial Supervisory Service DART

💡 3-Second Summary

Hanwha Systems’ subsidiary, HS USA Holdings Corp., has resolved to execute a shareholder-allocated rights offering to raise KRW 84.63B (USD 62M) for acquiring securities of another corporation.

📊 [Key Disclosure Details & Financial Highlights]

  1. Subsidiary Overview
  • Subsidiary Name: HS USA Holdings Corp.
  • Representative: Yeon-Bo Jeon
  • Main Business: Management of overseas subsidiaries
  • Major Subsidiary Status: Applicable
  • Total Assets of Subsidiary (as of end-2024): KRW 94,022,878,740
  • Ratio to Controlling Company’s Consolidated Total Assets (KRW 5.724T): 1.64%
  1. Details of Rights Offering & Capital Raising
  • Type and Number of New Shares: 62,000 Common Shares
  • Par Value & Issue Price Per Share: KRW 1,365,000 (USD 1,000 / Exchange rate of KRW 1,365.00/USD applied)
  • Total Issued Shares Prior to Capital Increase: 64,001 Common Shares
  • Purpose of Capital Raising: Acquisition of securities of another corporation (KRW 84,630,000,000 / approx. KRW 84.63B)
  • Method of Capital Increase: Rights offering allocated to shareholders (approx. 0.9687348 new shares per share)
  • Payment Date: July 3, 2025
  1. Other Important Matters
  • This disclosure reports the capital increase decision of a subsidiary in which Hanwha Systems holds a 100% equity stake.
  • Board Resolution Date: June 25, 2025 (Board approval date of the subsidiary)
  • Securities Registration Statement Exemption: Exempt (Not a public offering; the subsidiary is an unlisted overseas entity)
  • Schedule and details remain subject to potential changes depending on future progress.

📝 Editor’s Comment (Key Follow-up Checkpoint)

📌 Monitoring Subsidiary Payment Completion and Securities Acquisition Progress

This disclosure concerns a shareholder-allocated rights offering by 100% subsidiary HS USA Holdings Corp. to raise funds for acquiring securities in another entity. Verifying that the share payment is completed on the scheduled date (July 3, 2025) and tracking the subsidiary’s execution of the planned securities acquisition is essential for assessing whether the funding purpose is met and evaluating its consolidated financial impact. Related progress can be reviewed in future periodic filings, such as quarterly, half-year, and annual reports.

📢 Disclaimer & Source Information

Source: This content was structured and generated based on official filings from the Financial Supervisory Service’s DART system.

Investment Risk Warning: This material is provided for informational and language reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest entirely with the investor.

Contact: For compliance inquiries or copyright concerns, please contact ksb220805@gmail.com.

Search by
Company Name or Stock Ticker.
Disclosures, Defense

Post navigation

Previous Post: [Disclosure] Hanwha Systems (272210) – Decision on Acquisition of Shares and Equity Securities of Other Corporation / 2025-06-25
Next Post: [Disclosure] Hanwha Systems (272210) – Matters Related to Sustainability Report / 2025-06-25

Related Posts

  • [Disclosure] Hanwha Aerospace (012450) – Advance Notice of Financial Results Disclosure / 2025-10-16 Disclosures
  • [Disclosure] Hyundai Motor (005380) – Results of Annual General Meeting of Shareholders / 2025-03-20 Disclosures
  • [Disclosure] SK Hynix (000660 / SKHY) – Decision on Cash / Property Dividend / 2024-04-24 Semiconductors
  • [Disclosure] KEPCO (015760 / KEP) – (Correction) Decision on Cash and In-Kind Dividend / 2026-03-06 Disclosures
  • [Disclosure] Hyundai Motor (005380) – Investor Relations (IR) Announcement / 2026-02-24 Disclosures
  • [Disclosure] SK hynix (000660 / SKHY) – Decision on Acquisition of Shares and Investment Securities of Other Corporation / 2026-01-28 Semiconductors
  • [Disclosure] Celltrion (068270) – CHMP Recommendation for Marketing Authorization for CT-P41 (Prolia & Xgeva Biosimilar) / 2024-12-16 Disclosures
  • [Disclosure] SK hynix (000660 / SKHY) – Investor Relations (IR) Holding (Information Disclosure) / 2026-01-15 Semiconductors
  • [Disclosure] Hyundai Motor (005380) – Delisting of Shares from Foreign Securities Markets / 2024-12-20 Disclosures
  • [Disclosure] Celltrion (068270) – Provisional Earnings Release (Consolidated Basis) (Correction) / 2025-08-06 Disclosures
  • [Disclosure] Hanwha Ocean (042660) – Decision on Debt Guarantee for Others / 2025-09-29 Disclosures
  • [Disclosure] Celltrion (068270) – Application for Phase 3 Clinical Trial Plan for CT-P13 SC (Zymfentra) in Europe (Part 1 & 2) (Rheumatoid Arthritis) / 2024-08-27 Disclosures
  • [Disclosure] ISU PETASYS (007660) – Paid-in Capital Increase / 2025-01-23 Semiconductors
  • [Disclosure] Celltrion (068270) – Application for Phase 3 Clinical Trial Plan for CT-P55 (Cosentyx Biosimilar) in the U.S. / 2024-07-01 Disclosures

Copyright © 2026 K-Stock Briefing.

Powered by PressBook News Dark theme